Pfizer trial data looks into how long its vaccine lasts and its effectiveness against a variant
Pfizer says new trial data is giving a glimpse into how long its vaccine protection lasts, and how effective it is against one variant.
Pfizer says new trial data is giving a glimpse into how long its vaccine protection lasts, and how effective it is against one variant.
Pfizer says protection from its COVID-19 vaccine lasts at least six months after the second dose. The pharmaceutical company has been studying the vaccine in nearly 5,000 volunteers. Among that group, 77 people who were vaccinated tested positive for COVID-19.
The manufacturers of all three COVID-19 vaccines being used in the United States say they continue to conduct tests and are working to increase production capabilities.
Pfizer says its COVID-19 vaccine is effective in adolescents. The pharmaceutical company says clinical trial results showed 100% efficacy in kids ages 12-15. Researchers say there were no COVID-19 cases among the more than 100,000 participants given the vaccine.
Pfizer and BioNTech say they are now hoping to manufacture 2.5 billion doses of their coronavirus vaccine by the end of this year. This comes as the United States continues its push to get people vaccinated.
The Pfizer COVID-19 vaccine can now be stored at normal freezer temperature for two weeks, according to the European Medicines Agency. The EMA says that the change is supported by new stability data, and that the new storage option gives more flexibility with its distribution.
Pfizer has started testing its coronavirus vaccine in children under the age of 12.
Right now, the three COVID-19 vaccines on the U.S. market are for adults. You must be 18 or older to get Moderna and Johnson & Johnson vaccines, and 16 or older for the vaccine made by Pfizer. Clinical trials are now underway for younger children.
Officials with the South Carolina Department of Health and Environmental Control provided an update on the vaccine distribution efforts in the state.
COVID-19 vaccine makers tell Congress to expect a big jump in the delivery of doses over the coming month.